Список литературы

1. Баранов А.А., Полякова С.И., Байдакова Г.В., Бушуева Т.В., Вашурина Т.В., Потапов А.С., Журкова Н.В., Варичкина М.А. Наследственная тирозинемия I типа (серия "Болезни детского возраста от А до Я". Союз педиатров России). - Педиатрия. - 2012 - 60 с.

2. Баранов А.А., Намазова-Баранова Л.С., Боровик Т.Э., Ладодо К.С., Бушуева Т.В., Маслова О.И., Кузенкова Л.М., Журкова Н.В., Звонкова Н.Г. и др. Диетотерапия при наследственных болезнях аминокислотного обмена Методическое письмо. Москва. 2013. 97 с.

3. МР 2.3.1.2432-08 "Нормы физиологических потребностей в энергии и пищевых веществах для различных групп населения Российской Федерации" (утв. Главным государственным санитарным врачом РФ 18 декабря 2008 г.).

4. Полякова С.И. Савостьянов К.В., Пушков А.А. Наследственная тирозинемия 1-го типа: что нужно знать педиатрам. Журнал Практика педиатра. 2014 - Февраль. - С. 4 - 16.

5. Angileri F, Bergeron A, Morrow G, Lettre F, Gray G, Hutchin T, Ball S, Tanguay RM. Geographical and Ethnic Distribution of Mutations of the Fumarylacetoacetate Hydrolase Gene in Hereditary Tyrosinemia Type 1. JIMD Rep. 2015 Feb 15.

6. Bahador A, Dehghani SM, Geramizadeh B, Nikeghbalian S, Bahador M, Malekhosseini SA, Kazemi K, Salahi H. Liver Transplant for Children With Hepatocellular Carcinoma and Hereditary Tyrosinemia Type 1.Exp Clin Transplant. 2014 Mar 28.

7. Dehghani SM, Haghighat M, Imanieh MH, Karamnejad H, Malekpour A. Clinical and para clinical findings in the children with tyrosinemia referring for liver transplantation. Int J Prev Med. 2013 Dec; 4(12): 1380 - 5.

8. Dorothy E.M. Francis Diet for Sick Children Forth Edition. Dietary management of disoders of amino acid metabolism, organic acidaemias and urea cycle defects 1987.

9. Maiorana A, Malamisura M, Emma F, Boenzi S, Di Ciommo VM, Dionisi-Vici C. Early effect of NTBC on renal tubular dysfunction in hereditary tyrosinemia type 1. Mol Genet Metab. 2014 Nov; 113(3): 188 - 93.

10. Nakamura K, Matsumoto S, Mitsubuchi H, Endo F. Diagnosis and treatment of hereditary tyrosinemia in Japan. Pediatr Int. 2015 Feb; 57(1): 37 - 40.

11. van Ginkel WG, Gouw AS, van der Jagt EJ, de Jong KP, Verkade HJ, van Spronsen FJ. Hepatocellular carcinoma in tyrosinemia type 1 without clear increase of AFP. Pediatrics. 2015 Mar; 135(3): e749 - 52.

12. Zeybek AC, Kiykim E, Soyucen E, Cansever S, Altay S, Zubarioglu T, Erkan T, Aydin A. Hereditary tyrosinemia type 1 in Turkey: twenty year single-center experience. Pediatr Int. 2015 Apr; 57(2): 281 - 9.

13. Macias I., A., Bernardo-Seisdedos G. et al. Hereditary tyrosinemia type I-associated mutations in fumarylacetoacetate hydrolase reduce the enzyme stability and increase its aggregation rate. J. Biol. Chem. (2019) 294(35) 13051 - 13060. DOI: https://doi.org/10.1074/jbc.RA119.009367

14. Новиков П.В. Тирозинемия I типа: клиника, диагностика и лечение//Рос вестн перинатол и педиат. 2012. N Приложение. URL: https://cyberleninka.ru/article/n/tirozinemiya-i-tipa-klinika-diagnostika-i-lechenie

15. Larochelle J., Alvarez F., J.F. et al. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in . Mol. Gen. Metab., 107 (1) (2012), pp. 49 - 54

16. Baydakova GV, Ivanova TA, Mikhaylova SV, et al. The Unique Spectrum of Mutations in Patients with Hereditary Tyrosinemia Type 1 in Different Regions of the Russian Federation. JIMD Reports. 2019; 45: 89 - 93. DOI: 10.1007/8904_2018_144.

17. Russo P.A., Mitchell G.A., Tanguay R.M. Tyrosinemia: a review. Pediatr Dev Pathol 2001; 4(3): 212 - 221

18. Schady D.A., Roy A., Finegold M.J. Liver tumors in children with metabolic disorders. Transl Pediatr 2015; 4(4): 290 - 303. DOI: 10.3978/j.issn.2224 - 4336.2015.10.08

19. Weinberg A.G., Mize C.E., Worthen H.G. The occurrence of hepatoma in the chronic form of hereditary tyrosinemia. J Pediatr 1976; 88(3): 434 - 438. DOI: 10.1016/s0022-3476(76)80259-4

20. van Spronsen F.J., Berger R., Smit G.P., de Klerk J.B., Duran M., Bijleveld C.M. et al. Tyrosinaemia type I: orthotopic liver transplantation as the only definitive answer to a metabolic as well as an oncological problem. J Inherit Metab Dis1989; 12(Suppl 2): 339 - 342. DOI: 10.1007/bf03335416

21. van Spronsen FJ, Thomasse Y, Smit GPA, Leonard JV, Clayton PT, Fidler V, Berger R, et al: Hereditary tyrosinemia type I: A new clinical classification with difference in prognosis on dietary treatment. Hepatology. 1994; 20: 1187.

22. Mitchell GA, Lambert M, Tanguay RM: Hypertyrosinemia, in Scriver CR, Beaudet A, Sly W, Valle D (eds): The Metabolic and Molecular Bases of Inherited Disease, 7th ed. New York, McGraw-Hill, 1995, p 1077

23. Y., Berthier MT. (2017) Newborn Screening for Hereditary Tyrosinemia Type I in : Update. In: Tanguay R. (eds) Hereditary Tyrosinemia. Advances in Experimental Medicine and Biology, vol 959. Springer, Cham

24. Khanna Rajeev, Verma Sanjeev Kumar. Pediatric hepatocellular carcinoma. World J Gastroenterol. 2018 Sep 21; 24(35): 3980 - 3999. Published online 2018 Sep 21. doi: 10.3748/wjg.v24.i35.3980

25. Bartlett DC, Lloyd C, McKiernan PJ, Newsome PN. Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function. J Inherit Metab Dis. 2014 Sep; 37(5): 745 - 52. doi: 10.1007/s10545-014-9683-x

26. Dubois J, Garel L, Patriquin H, Paradis K, Forget S, Filiatrault D, Grignon A, et al: Imaging features of type 1 hereditary tyrosinemia: A review of 30 patients. Pediatr Radiol. 1996; 26: 845.

27. Mitchell GA, Larochelle J, Lambert M, Michaud J, Grenier A, Ogier H, Gauthier M, et al: Neurologic crises in hereditary tyrosinemia. New England Journal of Medicine, 322(7), 432 - 437. doi:10.1056/nejm199002153220704

28. Strife CF, Zuroweste EL, Emmett EA, Finelli VN, Petering HG, Berry HK: Tyrosinemia with acute intermittent porphyria: Aminolevulinic acid dehydratase deficiency related to elevated urinary aminolevulinic acid levels. J Pediatr. 1977; 90: 400

29. Glorieux FH: Rickets, the continuing challenge. N Engl J Med. 1991; 325: 1875.

30. Lindblad B, SP, S, Nordborg C, Solymar L, Velander H: Cardiomyopathy in fumarylacetoacetase deficiency (hereditary tyrosinaemia): A new feature of the disease. J Inherit Metab Dis. 1987; 10: 319.

31. Chinsky J. M., Singh R., Ficicioglu C. et al. Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations Genet Med. 2017 Dec; 19(12)

32. Jeffrey M Chinsky, MD, PhD, Rani Singh, PhD, RD, Can Ficicioglu, MD, PhD, Clara D M van Karnebeek, MD, PhD, Markus Grompe, MD, Grant Mitchell, MD, Susan E Waisbren, PhD, Muge Gucsavas-Calikoglu, MD, Melissa P Wasserstein, MD, Katie Coakley, PhD, RD, and C Ronald Scott, MD Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations Genet Med. 2017 Dec; 19(12)

33. https://emedicine.medscape.com/article/949816-workup

34. Faix, J.D. (2013). Biomarkers of sepsis. Critical Reviews in Clinical Laboratory Sciences, 50(1), 23 - 36. doi:10.3109/10408363.2013.764490

35. Pierrakos C, Velissaris D, Bisdorff M, Marshall JC, Vincent JL. Biomarkers of sepsis: time for a reappraisal. Crit Care. 2020 Jun 5; 24(1): 287

36. Deirdre A. Kelly (Editor)Diseases of the Liver and Biliary System in Children, 4th Edition ISBN: 978-1-119-04690-5 March 2017 Wiley-Blackwell 648 Pages

37. Development of newborn screening connect (NBS connect): a self-reported patient registry and its role in improvement of care for patients with inherited metabolic disorders. Orphanet J Rare Dis. 2017 Jul 19; 12(1): 132, https://depts.washington.edu/tyros/pdfs/New_Parents_Guide_to_Tyrosinemia.pdf

38. Nissenkorn A, Korman SH, Vardi O, Levine A, Katzir Z, Ballin A, Lerman-Sagie T. Carnitine-deficient myopathy as a presentation of tyrosinemia type I. J Child Neurol. 2001; 16: 642 - 4.

39. Sniderman King L, Trahms C, Scott CR. Tyrosinemia Type I. 2006 Jul 24 [Updated 2017 May 25]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993 - 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1515/

40. Corinne de Laet C, Dionisi-Vici C, Leonard JV, McKiernan P, Mitchell G, Monti L, de Baulny HO, Pintos-Morell G, U. Recommendations for the management of tyrosinaemia type 1. Orphanet J Rare Dis. 2013 Jan 11; 8: 8. doi: 10.1186/1750-1172-8-8

41. Barnby E. Tyrosinemia Type 1: An Overview of Nursing Care PEDIATRIC NURSING/2014/Vol. 40/No. 2/p.62-68. http://pediatricnursing.net/ce/2016/article40026190.pdf